We are hosting a conference call and live webcast on Thursday, November 5, at 8:00 a.m. ET to report and discuss our third quarter 2026 financial results and other business highlights. Instructions on how to join the webcast are available here: bit.ly/4jM8ZUZ

We’re live at #ASCAT2026 and are thrilled to connect with the #SickleCellDisease and #Thalassemia communities and our partners. We’re excited to share research updates and continue important conversations about these rare diseases. Visit us at Booth 24!

#AgiosNews: ENERGIZE-T Phase 3 results were published in The Lancet, highlighting that our first-in-class pyruvate kinase (PK) activator can reduce transfusion burden in patients with transfusion dependent #thalssemia. ​ ​ Read the publication: bit.ly/3ULb0qg

#AgiosNews: Today we reported our second quarter 2026 financial results and business highlights. Read our press release and tune into our webcast this morning at 8:00 a.m. ET: bit.ly/4fuZrv5

#AgiosNews: Our topline Phase 2 data showed hemoglobin improvements for our mid-stage pyruvate kinase (PK) activator, consistent with PK activation, but results did not establish differentiation to continue development in #SickleCellDisease. Read more: bit.ly/4vJvDjh

#AgiosNews: @US_FDA accepted the supplemental New Drug Application (sNDA) for our first-in-class pyruvate kinase (PK) activator in #SickleCellDisease with a Priority Review. The PDUFA goal date is November 1, 2026. Read more: bit.ly/4y37Z3v

We are hosting a conference call and live webcast on Thursday, July 30, at 8:00 a.m. ET to report and discuss our second quarter 2026 financial results and other business highlights. Instructions on how to join the webcast are available here: bit.ly/4xV1dg8

#AgiosNews: Today we presented detailed RISE UP Phase 3 results of our first-in-class pyruvate kinase (PK) activator in #SickleCellDisease, including new data reinforcing its anti-hemolytic profile, at the #EHA2026 Plenary Abstracts Session. Read more: bit.ly/4epCPuk

✈️ We're live at #EHA2026, ready to connect with the global #hematology community and present the latest data highlighting our first-in-class pyruvate kinase (PK) activator. Meet us at booth # A1.04 and visit our microsite for more information: bit.ly/444JpBq

#AgiosNews: We have obtained exclusive global rights to a novel, next‑generation, oral spleen tyrosine kinase (SYK) inhibitor from Oscotec, and will advance this for immune thrombocytopenia (ITP), a rare autoimmune blood disorder. Read more: bit.ly/437CJCg

#AgiosNews: We will not advance our next-generation oral pyruvate kinase (PK) activator in lower-risk myelodysplastic syndromes (LR-MDS), following Phase 2b results that did not meet our predefined threshold to support further development. Read more: bit.ly/3QbdSdQ

#AgiosNews: @EU_Commission granted authorization for our first-in-class oral pyruvate kinase (PK) activator in adults for the treatment of anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia. Read more: bit.ly/42RJo3r

#AgiosNews: We submitted an sNDA to the @US_FDA for U.S. accelerated approval of our first-in-class pyruvate kinase (PK) activator in #SickleCellDisease. We expect acceptance notice in the third quarter of 2026, following FDA’s 60-day review period. Read more: bit.ly/4ubwola

At #EHA2026, we’re excited to showcase new data highlighting our first-in-class pyruvate kinase (PK) activator – including a plenary session with RISE UP Phase 3 #SickleCellDisease trial results – and connect with the #hematology community. Read more: bit.ly/4d3BLNg

Members of our Leadership Team will participate in fireside chats at the Bank of America (May 12) and RBC Capital Markets (May 19) 2026 healthcare conferences. Live webcasts and replays will be on the Investors section of our website. Listen and learn more: bit.ly/4uycjW0

Great conversations at the 2026 @amcporg Annual Meeting. Our team’s #HEOR research on #SickleCellDisease confirms that progress demands system-wide approaches to address the real barriers patients face. #AMCP #RareDisease

We're at the 2026 @ASPHO_hq Conference, ready to explore scientific advances in pediatric #hematology and connect with #raredisease communities. Find us at booth #307 to learn about the latest progress from our pyruvate kinase activation portfolio. #ASPHO2026

#AgiosNews: Today we reported our first quarter 2026 financial results, along with recent business highlights. Read the press release and tune into the webcast this morning at 8:00 a.m. ET: bit.ly/4mXY2iN

Our 2026 Environmental, Social, and Governance (ESG) report is now available. It highlights our partnerships with rare disease communities to advance science and access to new medicines, and our commitment to a safe, inclusive, and purpose-driven workplace: bit.ly/4u2N6CP

We are hosting a conference call and live webcast on Wednesday, April 29, at 8:00 a.m. ET to report and discuss our first quarter 2026 financial results and other business highlights. Instructions on how to join the webcast are available here: bit.ly/4vkGm4P